

# **Navana Pharmaceuticals PLC.**

## **Interim Financial Statements (Un-audited) for Second Quarter (Q2), FY 2023-2024**

*Period: 1<sup>st</sup> July - 31<sup>th</sup> December 2023*



**Navana Pharmaceuticals PLC**  
**Statement of Financial Position (Un-audited)**  
**As at 31 December 2023**


(Amount in BDT)


Particulars	Notes	As at	
		31-Dec-2023	30-Jun-2023
<b>Assets</b>			
<b>Non-Current Assets:</b>			
Property, Plant and Equipment	3.00	4,066,678,159	3,810,381,680
Intangible Asset	3.01	440,000	550,000
Capital Work in Progress	4.00	686,876,931	614,665,799
Right-of-Use Asset	5.00	175,172,885	207,108,483
Investment in Marketable Securities (Fair Value)	6.00	139,503,215	167,619,834
<b>Total Non-Current Assets</b>		<b>5,068,671,190</b>	<b>4,800,325,795</b>
<b>Current Assets:</b>			
Inventories	7.00	1,257,349,333	1,104,799,038
Trade and Other Receivables	8.00	1,171,498,351	801,236,634
Advances, Deposits and Prepayments	9.00	2,076,553,466	2,117,171,560
Goods In Transit	10.00	385,486,763	325,281,182
Cash and Cash Equivalents	11.00	315,360,107	440,930,216
<b>Total Current Assets</b>		<b>5,206,248,021</b>	<b>4,789,418,629</b>
<b>Total Assets</b>		<b>10,274,919,211</b>	<b>9,589,744,424</b>
<b>Equity And Liabilities</b>			
<b>Equity:</b>			
Paid-up Share Capital	12.00	1,074,162,170	1,074,162,170
Share Premium	13.00	448,170,069	448,170,069
Revaluation Reserve	14.00	1,848,295,335	1,848,295,335
Capital Reserve		605,590,148	605,590,148
Unrealized Gain/ (Loss) Reserve	6.00	(63,941,398)	(46,800,998)
Retained Earnings		527,705,473	443,028,348
<b>Total Equity:</b>		<b>4,439,981,797</b>	<b>4,372,445,072</b>
<b>Liabilities</b>			
<b>Non-Current Liabilities:</b>			
Loan from Directors	15.00	30,000,000	30,000,000
Lease Liabilities	16.02	72,509,180	89,596,112
Long Term Loan	17.02	153,529,529	90,627,308
Deferred Tax Liability	18.00	159,633,784	152,111,700
<b>Total Non-Current Liabilities</b>		<b>415,672,492</b>	<b>362,335,120</b>
<b>Current Liabilities:</b>			
Short Term Loan	19.00	4,411,176,229	4,066,050,635
Lease Liabilities (Current Maturity)	16.01	24,691,658	34,719,611
Long Term Loan (Current Maturity)	17.01	17,803,655	18,090,344
Trade and Other Payables	20.00	820,973,414	731,095,269
Unclaim Dividend Payable	39.00	4,978,884	5,008,375
Dividend Payable		139,641,082	-
<b>Total Current Liabilities</b>		<b>5,419,264,922</b>	<b>4,854,964,234</b>
<b>Total Liabilities</b>		<b>5,834,937,414</b>	<b>5,217,299,353</b>
<b>Total Equity and Liabilities</b>		<b>10,274,919,211</b>	<b>9,589,744,425</b>
<b>Net Asset Value (NAV) Per Share</b>	<b>30.00</b>	<b>41.33</b>	<b>40.71</b>


Annexed notes are integral part of these financial statement.

  
**Chief Financial Officer**

  
**Company Secretary**

  
**Managing Director**

  
**Director**

  
**Director**

**Navana Pharmaceuticals PLC**  
**Statement of Profit or Loss and Other Comprehensive Income (Un-audited)**  
**For the period from 01 July 2023 to 31 December 2023**

(Amount in BDT)


Particulars	Notes	Half Yearly		Second Quarter	
		July-Dec'2023	July-Dec'2022	Oct-Dec'2023	Oct-Dec'2022
<b>Net Sales</b>	21.00	<b>3,283,637,823</b>	<b>2,731,985,726</b>	<b>1,652,116,111</b>	<b>1,395,860,103</b>
Less: Cost of Good Sold	22.00	1,753,983,777	1,475,493,093	878,668,658	747,501,671
<b>Gross Profit</b>		<b>1,529,654,046</b>	<b>1,256,492,634</b>	<b>773,447,453</b>	<b>648,358,432</b>
<b>Less: Operating Expenses</b>					
Administrative Expenses	23.00	101,101,977	100,786,936	51,550,092	59,288,683
Selling & Marketing Expenses	24.00	721,429,445	616,649,994	373,509,023	332,820,480
Distribution Expenses	25.00	237,839,980	188,586,128	121,603,136	95,129,309
<b>Total Operating Expenses:</b>		<b>1,060,371,402</b>	<b>906,023,058</b>	<b>546,662,251</b>	<b>487,238,472</b>
<b>Operating Profit</b>		<b>469,282,643</b>	<b>350,469,575</b>	<b>226,785,202</b>	<b>161,119,960</b>
Less: Finance Expenses	26.00	178,625,532	142,607,229	101,298,283	77,309,339
Add: Other Income/(loss)	27.00	13,192,764	(15,041,693)	10,053,512	(3,675,944)
<b>Profit before WPPF &amp; Tax</b>		<b>303,849,875</b>	<b>192,820,653</b>	<b>135,540,431</b>	<b>80,134,677</b>
Contribution to WPPF		14,469,042	9,181,936	6,454,306	3,815,937
<b>Profit before tax</b>		<b>289,380,834</b>	<b>183,638,717</b>	<b>129,086,125</b>	<b>76,318,740</b>
<b>Less: Income Tax</b>		<b>65,062,627</b>	<b>40,081,797</b>	<b>24,318,009</b>	<b>5,392,244</b>
Current Tax	28.00	57,540,543	35,516,996	21,948,248	18,993,226
Deferred Tax Expense/(Income)		7,522,084	4,564,800	2,369,760	(13,600,983)
<b>Profit after Tax</b>		<b>224,318,207</b>	<b>143,556,921</b>	<b>104,768,117</b>	<b>70,926,496</b>
<b>Other Comprehensive Income</b>					
Unrealized Gain/(loss) on Marketable Security		(17,140,400)	19,167,038	(9,315,188)	7,460,356
<b>Total Comprehensive Income</b>		<b>207,177,807</b>	<b>162,723,959</b>	<b>95,452,928</b>	<b>78,386,852</b>
<b>Earnings Per Share (EPS)</b>	29.00	<b>2.09</b>	<b>1.57</b>	<b>0.98</b>	<b>0.77</b>

Annexed notes are integral part of these financial statement.

  
Chief Financial Officer

  
Company Secretary

  
Managing Director

  
Director

  
Director

Navana Pharmaceuticals PLC  
Statement of Changes in Equity (Un-audited)  
For the period from 01 July 2023 to 31 December 2023

(Amount in BDT)

Particulars	Share Capital	Share Premium	Liability against Share Money	Revaluation Reserve	Capital Reserve	Unrealized Gain / (Loss) Reserve	Retained Earnings	Total
Balance as at 1 July 2023	1,074,162,170	448,170,069	-	1,848,295,335	605,590,148	(46,800,998)	443,028,348	4,372,445,072
Profit after Tax	-	-	-	-	-	-	224,318,207	224,318,207
13% Cash Dividend for YE 30 June 2023	-	-	-	-	-	-	(139,641,082)	(139,641,082)
Less: Adj with IPO Expense	-	-	-	-	-	-	-	-
Adj. to Unrealized Gain / (Loss) on FVOCI	-	-	-	-	-	(17,140,400)	-	(17,140,400)
<b>Balance as at 31 December 2023</b>	<b>1,074,162,170</b>	<b>448,170,069</b>	<b>-</b>	<b>1,848,295,335</b>	<b>605,590,148</b>	<b>(63,941,398)</b>	<b>527,705,473</b>	<b>4,439,981,797</b>

Statement of Changes in Equity (Un-audited)  
For the period from 01 July 2022 to 31 December 2022

(Amount in BDT)

Particulars	Share Capital	Share Premium	Liability against Share Money	Revaluation Reserve	Capital Reserve	Unrealized Gain / (Loss) Reserve	Retained Earnings	Total
Balance as at 1 July 2022	802,301,500	-	-	1,966,271,633	605,590,148	(95,356,927)	204,242,971	3,483,049,325
Profit after Tax	-	-	-	-	-	-	143,556,922	143,556,922
Received from IPO Share Subscription	-	-	750,000,018	-	-	-	-	750,000,018
Allotment of Shares for IPO	271,860,670	478,139,348	(750,000,018)	-	-	-	-	-
11% Cash Dividend for YE 30 June 2022	-	-	-	-	-	-	(118,157,839)	(118,157,839)
Less: Adj with IPO Expense	-	(27,929,786)	-	-	-	-	-	(27,929,786)
Adj. to Unrealized Gain / (Loss) on FVOCI	-	-	-	-	-	19,167,038	-	19,167,038
<b>Balance as at 30 June 2023</b>	<b>1,074,162,170</b>	<b>450,209,562</b>	<b>-</b>	<b>1,966,271,633</b>	<b>605,590,148</b>	<b>(76,189,889)</b>	<b>229,642,054</b>	<b>4,249,685,678</b>


Annexed notes are integral part of these financial statement.



Chief Financial Officer



Company Secretary



Managing Director



Director




Director

**Navana Pharmaceuticals PLC**  
**Statement of Cash Flows (Un-audited)**  
**For the period from 01 July 2023 to 31 December 2023**

Particulars	Notes	July-Dec'2023	July-Dec'2022
<b>Cash Flows from Operating Activities:</b>		<b>93,133,612</b>	<b>79,655,306</b>
Cash Receipts from Customers		2,918,222,249	2,675,574,518
Cash Receipts from Other Income		11,964,064	35,607,023
Cash Paid to Suppliers		(1,604,567,549)	(1,501,750,129)
Cash paid to Employees and Others		(556,383,157)	(489,455,504)
Cash paid to Operational Expenses		(610,936,229)	(592,072,825)
Advance Income Tax Paid		(65,165,766)	(48,247,777)
		<b>(428,830,158)</b>	<b>(858,951,948)</b>
<b>Cash Flows from Investing Activities:</b>			
Property, Plant and Equipment		(441,374,221)	(846,628,977)
Realized Gain/(loss) from Sale of Marketable Securities		823,584	(21,762,449)
Cash received from Dividend Income		744,262	671,590
Cash Received/(Paid) from Investment in Marketable Securities		10,976,217	8,767,888
		<b>210,040,204</b>	<b>1,362,024,941</b>
<b>Cash Flows from Financing Activities:</b>			
Increase/ (Decrease) in Lease Liabilities		(27,114,885)	(932,839)
Increase/ (Decrease) in Long Term Loan		62,615,532	(137,849,949)
Increase/ (Decrease) in Short Term Loan		345,125,594	920,658,223
Cash Received from IPO Proceed		-	750,000,018
Payment for IPO Expenses		-	(16,036,004)
Bank & Lease Interest Paid		(170,556,546)	(153,814,509)
Unclaimed dividend Paid		(29,491)	-
		<b>(125,656,341)</b>	<b>582,728,298</b>
<b>Increase/(Decrease) in cash &amp; cash equivalents</b>		<b>440,930,216</b>	<b>66,427,585</b>
Cash and Cash Equivalents at Beginning of year		86,233	1,333,733
Effect of exchange rate changes on Cash and Cash Equivalents		<b>315,360,107</b>	<b>650,489,616</b>
<b>Cash and Cash Equivalents at end of year</b>	11.00	<b>315,360,107</b>	<b>650,489,616</b>
<b>Net operating cash flows per share</b>	31.00	<b>0.87</b>	<b>0.87</b>

Annexed notes are integral part of these financial statement.

  
**Chief Financial Officer**

  
**Company Secretary**

  
**Managing Director**

  
**Director**

  
**Director**

**Navana Pharmaceuticals PLC**  
**Notes to the Interim Financial Statements**  
**For the period 01 July 2023 to 31 December 2023**

**1.0 About the Company**

**1.01 Legal Form of the Company**

Navana Pharmaceuticals PLC was incorporated in Bangladesh on 31 March 1986 vide registration no. C-15428/994 under the Companies Act-1913 (replaced by the Companies Act-1994) as a Private Company Limited by shares. The company was converted into a Public Limited Company on 30 December 2020.

**1.02 Address of the Registered Office and Factory**

The address of the Company's registered office is 125/A Islam Chamber Motijheel C/A Dhaka 1000. Corporate office address is House 99, Road 4, Block # B, Banani Dhaka-1213, Bangladesh. The Company has its factory in Rupshi, Narayangonj and several depots around the country.

**1.03 Nature of Business Activities**

The principal activities of the Company are manufacturing, distribution and marketing of pharmaceutical and veterinary products and sales of the produced items in the domestic and foreign market.

**2.00 Basis of Preparation and Presentation of Financial Statements**

**2.01 Preparation and Presentation of Financial Statements of the Company**

These Financial Statements are the unaudited Interim Financial Statements (here after 'the Interim Financial Statements') of Navana Pharmaceuticals Ltd.

These interim financial statements should be read in conjunction with the Financial Statements for the Year ended December 31, 2023 (hereafter referred to as the "Annual Financial Statements"), as they provide an update to previously reported information. The accounting policies used are consistent with those used in the Annual Financial Statements. These financial statements have been prepared in a condensed form with selected notes following IAS 34: Interim Financial Reporting. The presentation of the Interim Financial Statements is consistent with the Annual Financial Statements. Where necessary, the comparatives have been reclassified or extended to take into account any presentational changes made in the Annual Financial Statements. The preparation of the Interim Financial Statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities at the date of the Interim Financial Statements. If in the future such estimates and assumptions, which are based on management's best judgment at the date of the Interim Financial Statements, deviate from the actual, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

**2.02 Statement of Compliance**

The Financial Statements have been prepared in compliance with the requirements of the Companies Act, 1994 and other relevant local laws as applicable and in accordance with the applicable International Accounting Standards (IASs), The Securities and Exchange Rules, 2020 and International Financial Reporting Standards (IFRSs) adopted by the Institute of Chartered Accountants of Bangladesh (ICAB) and others laws and regulations applicable for the company.

**2.03 Regulatory Compliances**

As required by the Company, the management complies with the following major legal provisions in addition to the Companies Act 1994 and other applicable laws and regulations:

- a) The Income Tax Ordinance 1984 and Income Tax Rules 2023
- b) The Income Tax Rules 1984 and Income Tax Rules 2023
- c) The Value Added Tax and Supplementary Duty Act 2012;
- d) The Value Added Tax and Supplementary Duty Rules 2016;
- e) The Customs Act, 1969 and Customs Act 2023
- f) Bangladesh Labour Law, 2006 (Amended 2018);
- g) Negotiable Instrument Act, 1881; and
- h) The Securities and Exchange Rules, 2020.

**2.04 Basis of Measurement**

The Financial Statements have been prepared on a going concern basis under the historical cost convention applying accrual basis of accounting in accordance with the International Financial Reporting Standards (IFRS's).

The financial statements have been prepared on historical cost convention following the accrual concept of accounting, except for Property, plant & equipment which has been presented under the revaluation model. Investment in shares is valued at par value and cash flow statement has been prepared on cash basis.

## 2.05 Reporting Period and Comparative Information

The Financial Statements cover 06 months period starting from July 01, 2023 to December 31, 2023

Certain comparative amounts have been re-classified & rearranged to conform to the current period's presentation and all numerical information in the current financial statements as below:

- Statements of Financial Position as of the end of the preceding financial period;
- Statements of Comprehensive Income for the comparable of the preceding financial period;
- Statements of Changes in Equity for the comparable of the preceding financial period;
- Statement of Cash Flows for the comparable of the preceding financial period;

Narrative and descriptive information for comparative information has also been disclosed as required by IASs & IFRSs whenever it is relevant for the understanding of the current Period financial statements.

## 2.06 Rearrangement of Financial Statement:

The previous period's figure has been rearrangement whenever considered necessary to ensure comparability with the current period presentation as per IAS 8 "Accounting Policies, Changes in Accounting Estimates and Errors".

## 2.07 Functional and Presentation Currency

The financial statements are prepared and presented in Bangladesh Currency (Taka), which is the company's functional currency. All financial information presented has been rounded off to the nearest Taka except where indicated otherwise.

## 2.08 Property, Plant and Equipment (PPE)

### Recognition and Measurement:

Items of property, plant & equipment are measured at cost or revalued amount less accumulated depreciation and impairment losses, if any in accordance with IAS 16: Property, Plant and Equipment. Cost includes expenditure that are directly attributable to the acquisition of the assets. The company has adopted 'Revaluation Model' for stating property, plant & equipment.

### Maintenance Activities

The company incurs maintenance costs for all its major items of property, plant and equipment. Repair and maintenance costs are charged as expenses when incurred.

### Subsequent Costs

The cost of replacing a part of an item of property, plant and equipment is recognized in the carrying amount of the item if it is probable that future economic benefits associated with the item will flow to the entity and the cost of the item can be measured reliably. All other repair and maintenances costs are charged to the Statement of Profit or Loss and Other Comprehensive Income during the financial period in which they incurred.

### Retirements and Disposals

On disposal of fixed assets, the cost and accumulated depreciation are eliminated and gain or loss on such disposal is reflected in the statement of Profit or Loss and Other Comprehensive Income, which is determined with reference to the net book value of the assets and net sales proceeds.

### Depreciation

Depreciation is provided to amortize the cost of the assets after commissioning, over the period of their expected useful lives, in accordance with the provisions of IAS 16: Property, Plant and Equipment.

Depreciation on Property, Plant and Equipment has been compute during the periods using reducing balance method except Land & Land Development. Depreciation has been charged on addition when the related PPE are available.

After considering the useful life of assets as per IAS 16, the annual depreciation rates have been applied as under which is considered reasonable by the management.

### Rate of Depreciation:

Particulars	Rate	Particulars	Rate
<b>Land and Land Development</b>		<b>Vehicles</b>	
Land and Land Development	Nil	Transport & Vehicles	20%
<b>Building &amp; Other Construction</b>		Motor Cycle	20%
Factory Building	10%	<b>Furniture &amp; Fixture</b>	
Office Decoration	10%	Furniture & Fixtures	10%
Pump House Construction	20%	Rack & Pallets	15%

Particulars	Rate	Particulars	Rate
Store Room	15%	<b>Office Equipment's</b>	
Office Room Extension	10%	Fire Extinguishers	15%
Factory Decoration	10%	Office Equipment's	15%
Factory Wall	10%	Air Cooler	20%
Pre Fabrication Building	10%	Cookeries & Cutleries	10%
Solvent Store	15%	Telephone Line Installation	15%
<b>Plant &amp; Machinery</b>		Photocopier & Fax Machine	20%
Plant & Machinery	20%	Projector	15%
Electrical Installation	20%	Refrigerator	20%
Generator	20%	Mobile	20%
Gas Line Installation	20%	<b>Computer &amp; IT Accessories</b>	
Spare Parts	20%	Computer	30%
ETP	20%	IT Accessories	30%
Electric Sub Station	20%	<b>Other Assets</b>	
<b>Lab Equipment</b>		Sundry Assets	15%
Quality Control Equipment	15%	Books	10%
Tools & Equipment's	15%	Software	20%

#### 2.09 Intangible Assets

Software are amortized over 5 periods based on straight line method from the date when assets are available for use. The amount of amortization has been presented under the statement of rate of amortization on software is as under.

#### 2.10 Events after the Reporting Period

Events after the reporting period that provide additional information about the company's position at the date of Statement of Financial Position or those that indicate that the going concern assumption is not appropriate are reflected in the financial statements. Events after reporting period that are not adjusting events are disclosed in the notes when material.

#### 2.11 Company Name Change to Navana Pharmaceuticals PLC

In accordance with the Amendment of The Companies Act 1994 (Amendment up to 2020), the company has decided to change its name from Navana Pharmaceuticals Ltd. to Navana Pharmaceuticals PLC. All necessary regulatory approvals have already been obtained.



Notes	Particulars	Amount in BDT	
		31/Dec/23	30/Jun/23
<b>3.00 Property, Plant and Equipment: Tk. 4,066,678,159</b>			
	This is made up as follows: (details shown in Annex A)		
	<b>Cost</b>		
	Opening Balance	2,650,971,843	2,101,724,213
	Addition during the period	350,203,905	549,247,630
	Adjustment/disposal during the period	(5,065,212)	-
	<b>Closing Balance</b>	<b>2,996,110,536</b>	<b>2,650,971,843</b>
	<b>Revaluation</b>		
	Opening Balance	1,966,271,632	1,966,271,632
	Adjustment due to revaluation during the period	-	-
	<b>Closing Balance</b>	<b>1,966,271,632</b>	<b>1,966,271,632</b>
	<b>Total Cost &amp; Revaluation</b>	<b>4,962,382,168</b>	<b>4,617,243,475</b>
	<b>Depreciation</b>		
	Opening Balance	806,861,796	646,158,480
	Charged during the period	93,693,132	160,703,316
	Adjustment during the period	(4,850,919)	-
	<b>Closing Balance</b>	<b>895,704,009</b>	<b>806,861,796</b>
	<b>Written Down Value</b>	<b>4,066,678,159</b>	<b>3,810,381,680</b>
<b>3.01 Intangible Assets: Tk. 440,000</b>			
	This is made up as follows:		
	<b>Cost</b>		
	Opening Balance	1,100,000	1,100,000
	Addition during the period	-	-
	<b>Total Cost</b>	<b>1,100,000</b>	<b>1,100,000</b>
	<b>Depreciation</b>		
	Opening Balance	550,000	330,000
	Charged during the period	110,000	220,000
	<b>Closing Balance</b>	<b>660,000</b>	<b>550,000</b>
	<b>Written Down Value</b>	<b>440,000</b>	<b>550,000</b>
<b>4.00 Capital Work In Progress: Tk. 686,876,931</b>			
	This is made up as follows:		
	Opening Balance	614,665,799	403,007,534
	<b>Addition during the period:</b>		
	Construction of new utility and engineering building	40,859,107	51,459,605
	Refurbishment of Cephalosporin Unit	72,998,035	105,232,976
	Warehouse Construction	138,185,530	450,996,699
	General Liquid Facility with Dispensing Area	21,448,929	-
	Animal Health Facility	919,401	-
		<b>889,076,801</b>	<b>1,010,696,814</b>
	<b>Less: Capitalized during the period</b>		
	Capitalized in Factory Building	(202,199,870)	(396,031,015)
	<b>Closing Balance</b>	<b>686,876,931</b>	<b>614,665,799</b>
<b>5.00 Right-of-Use Asset: Tk. 175,172,885</b>			
	This is made up as follows: (Details shown in Annex B)		
	<b>Cost</b>		
	Opening Balance	<b>545,842,791</b>	<b>493,270,381</b>
	On Lease Vehicles	501,942,299	468,009,472
	On Rental Asset	43,900,492	22,153,852
	Addition during the period on Rental assets	-	52,572,411